EPISODE · Nov 11, 2025 · 9 MIN
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
from BiotechTV - News · host BiotechTV
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs.
Embed this episode
Ready to play
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
0:00
9:37
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 9 minutes long.
When was this BiotechTV - News episode published?
This episode was published on November 11, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!